Jennifer K. Richer - Publications

University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 
Oncology, Cell Biology, Molecular Biology

44 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Gordon MA, Babbs B, Cochrane DR, Bitler B, Richer JK. The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing. Molecular Carcinogenesis. PMID 30294913 DOI: 10.1002/mc.22919  0.64
2018 Rogers TJ, Christenson JL, Greene LI, O'Neill KI, Williams MM, Gordon MA, Nemkov T, D'Alessandro A, DeGala GD, Shin J, Tan AC, Cittelly DM, Lambert JR, Richer JK. Reversal of Triple-negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immune-Suppression. Molecular Cancer Research : McR. PMID 30213797 DOI: 10.1158/1541-7786.MCR-18-0246  0.48
2017 Wellberg EA, Checkley LA, Giles ED, Johnson SJ, Oljira R, Wahdan-Alaswad R, Foright RM, Dooley G, Edgerton SM, Jindal S, Johnson GC, Richer JK, Kabos P, Thor AD, Schedin P, et al. The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Hormones & Cancer. PMID 28741260 DOI: 10.1007/s12672-017-0302-9  0.32
2017 Barton VN, Christenson JL, Gordon MA, Greene LI, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D'Amato NC, Elias A, Richer JK. Androgen receptor supports an anchorage-independent, cancer stem cell-like population in triple-negative breast cancer. Cancer Research. PMID 28512248 DOI: 10.1158/0008-5472.CAN-16-3240  0.56
2017 Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle JD, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. Molecular Cancer Therapeutics. PMID 28468774 DOI: 10.1158/1535-7163.MCT-17-0111  0.48
2017 Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, Richer JK. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. Hormones & Cancer. PMID 28194662 DOI: 10.1007/s12672-017-0285-6  0.56
2016 Heinz RE, Rudolph MC, Ramanathan P, Spoelstra NS, Butterfield KT, Webb PG, Babbs BL, Gao H, Chen S, Gordon MA, Anderson SM, Neville MC, Gu H, Richer JK. Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis. Development (Cambridge, England). PMID 27729410 DOI: 10.1242/dev.139642  0.56
2016 D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Molecular Cancer Research : McR. PMID 27565181 DOI: 10.1158/1541-7786.MCR-16-0167  0.56
2016 Barton VN, Gordon MA, Richer JK, Elias A. Anti-androgen therapy in triple-negative breast cancer. Therapeutic Advances in Medical Oncology. 8: 305-8. PMID 27482289 DOI: 10.1177/1758834016646735  0.44
2016 Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, Richer JK. Dicer Expression in Estrogen Receptor Positive versus Triple-Negative Breast Cancer: An Antibody Comparison. Human Pathology. PMID 27260947 DOI: 10.1016/j.humpath.2016.05.014  0.56
2015 D'Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, Nemkov TG, D'Alessandro A, Hansen KC, Richer JK. A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer. Cancer Research. PMID 26363006 DOI: 10.1158/0008-5472.CAN-15-2011  0.64
2015 Barton VN, D'Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Hormones & Cancer. PMID 26201402 DOI: 10.1007/s12672-015-0232-3  0.64
2015 Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Molecular Cancer Therapeutics. 14: 769-78. PMID 25713333 DOI: 10.1158/1535-7163.MCT-14-0926  0.56
2015 Niemeyer BF, Parrish JK, Spoelstra NS, Joyal T, Richer JK, Jedlicka P. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes. Plos One. 10: e0116895. PMID 25603314 DOI: 10.1371/journal.pone.0116895  0.56
2014 Wahdan-Alaswad RS, Cochrane DR, Spoelstra NS, Howe EN, Edgerton SM, Anderson SM, Thor AD, Richer JK. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Hormones & Cancer. 5: 374-89. PMID 25213330 DOI: 10.1007/s12672-014-0188-8  0.64
2014 Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Science Translational Medicine. 6: 229ra41. PMID 24670685 DOI: 10.1126/scitranslmed.3008326  0.64
2014 Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, ... ... Richer JK, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Research : Bcr. 16: R7. PMID 24451109 DOI: 10.1186/bcr3599  0.64
2013 Wahdan-Alaswad R, Fan Z, Edgerton SM, Liu B, Deng XS, Arnadottir SS, Richer JK, Anderson SM, Thor AD. Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle (Georgetown, Tex.). 12: 3759-69. PMID 24107633 DOI: 10.4161/cc.26641  0.64
2013 D'Amato NC, Howe EN, Richer JK. MicroRNA regulation of epithelial plasticity in cancer Cancer Letters. 341: 46-55. PMID 23228634 DOI: 10.1016/j.canlet.2012.11.054  0.64
2013 Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4 Oncogene. 32: 2555-2564. PMID 22751119 DOI: 10.1038/onc.2012.275  0.64
2012 Howe EN, Cochrane DR, Cittelly DM, Richer JK. miR-200c Targets a NF-κB Up-Regulated TrkB/NTF3 Autocrine Signaling Loop to Enhance Anoikis Sensitivity in Triple Negative Breast Cancer Plos One. 7. PMID 23185507 DOI: 10.1371/journal.pone.0049987  0.64
2012 Cittelly DM, Dimitrova I, Howe EN, Cochrane DR, Jean A, Spoelstra NS, Post MD, Lu X, Broaddus RR, Spillman MA, Richer JK. Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Molecular Cancer Therapeutics. 11: 2556-65. PMID 23074172 DOI: 10.1158/1535-7163.MCT-12-0463  0.64
2012 Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: Opposing effects on epithelial identity Journal of Mammary Gland Biology and Neoplasia. 17: 65-77. PMID 22350980 DOI: 10.1007/s10911-012-9244-6  0.64
2012 Cochrane DR, Jacobsen BM, Connaghan KD, Howe EN, Bain DL, Richer JK. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer Molecular and Cellular Endocrinology. 355: 15-24. PMID 22330642 DOI: 10.1016/j.mce.2011.12.020  0.64
2012 Cochrane DR, Spoelstra NS, Richer JK. The role of miRNAs in progesterone action. Molecular and Cellular Endocrinology. 357: 50-9. PMID 21952083 DOI: 10.1016/j.mce.2011.09.022  0.64
2011 Howe EN, Cochrane DR, Richer JK. Targets of miR-200c mediate suppression of cell motility and anoikis resistance Breast Cancer Research. 13. PMID 21501518 DOI: 10.1186/bcr2867  0.64
2011 Cochrane DR, Cittelly DM, Richer JK. Steroid receptors and microRNAs: relationships revealed. Steroids. 76: 1-10. PMID 21093468 DOI: 10.1016/j.steroids.2010.11.003  0.64
2010 Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D, Richer JK. MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer Hormones and Cancer. 1: 306-319. PMID 21761362 DOI: 10.1007/s12672-010-0043-5  0.64
2010 Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Molecular Cancer. 9: 317. PMID 21172025 DOI: 10.1186/1476-4598-9-317  0.64
2010 Cittelly DM, Richer JK, Sartorius CA. Ovarian steroid hormones: what's hot in the stem cell pool? Breast Cancer Research : Bcr. 12: 309. PMID 20825628 DOI: 10.1186/bcr2627  0.48
2010 Wright JA, Richer JK, Goodall GJ. microRNAs and EMT in mammary cells and breast cancer. Journal of Mammary Gland Biology and Neoplasia. 15: 213-23. PMID 20499142 DOI: 10.1007/s10911-010-9183-z  0.64
2010 Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers. Journal of Oncology. 2010: 821717. PMID 20049172 DOI: 10.1155/2010/821717  0.64
2009 Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents Molecular Cancer Therapeutics. 8: 1055-1066. PMID 19435871 DOI: 10.1158/1535-7163.MCT-08-1046  0.64
2009 Dimitrova IK, Richer JK, Rudolph MC, Spoelstra NS, Reno EM, Medina TM, Bradford AP. Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient. Fertility and Sterility. 91: 2650-63. PMID 18672237 DOI: 10.1016/j.fertnstert.2008.03.071  0.64
2008 Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 912-23. PMID 18487993 DOI: 10.1038/modpathol.2008.82  0.64
2008 Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VF, Elias AD, Horwitz KB. Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers: tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Research and Treatment. 112: 489-501. PMID 18338247 DOI: 10.1007/s10549-008-9923-6  0.64
2008 Harvell DM, Spoelstra NS, Singh M, McManaman JL, Finlayson C, Phang T, Trapp S, Hunter L, Dye WW, Borges VF, Elias A, Horwitz KB, Richer JK. Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Research and Treatment. 112: 475-88. PMID 18327671 DOI: 10.1007/s10549-008-9897-4  0.64
2006 Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 19: 1593-605. PMID 16980945 DOI: 10.1038/modpathol.3800696  0.64
2006 Tung L, Abdel-Hafiz H, Shen T, Harvell DM, Nitao LK, Richer JK, Sartorius CA, Takimoto GS, Horwitz KB. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B. Molecular Endocrinology (Baltimore, Md.). 20: 2656-70. PMID 16762974 DOI: 10.1210/me.2006-0105  0.64
2006 Spoelstra NS, Manning NG, Higashi Y, Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB, Richer JK. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Research. 66: 3893-902. PMID 16585218 DOI: 10.1158/0008-5472.CAN-05-2881  0.56
2005 Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 97: 328-41. PMID 16157482 DOI: 10.1016/j.jsbmb.2005.06.032  0.64
2005 Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Molecular Endocrinology (Baltimore, Md.). 19: 574-87. PMID 15563544 DOI: 10.1210/me.2004-0287  0.64
2003 Takimoto GS, Tung L, Abdel-Hafiz H, Abel MG, Sartorius CA, Richer JK, Jacobsen BM, Bain DL, Horwitz KB. Functional properties of the N-terminal region of progesterone receptors and their mechanistic relationship to structure. The Journal of Steroid Biochemistry and Molecular Biology. 85: 209-19. PMID 12943706 DOI: 10.1016/S0960-0760(03)00197-3  0.64
2002 Jacobsen BM, Richer JK, Schittone SA, Horwitz KB. New human breast cancer cells to study progesterone receptor isoform ratio effects and ligand-independent gene regulation. The Journal of Biological Chemistry. 277: 27793-800. PMID 12021276 DOI: 10.1074/jbc.M202584200  0.64
Show low-probability matches.